Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2010

01-03-2010

Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer

Authors: Raj Chari, Kelsie L. Thu, Ian M. Wilson, William W. Lockwood, Kim M. Lonergan, Bradley P. Coe, Chad A. Malloff, Adi F. Gazdar, Stephen Lam, Cathie Garnis, Calum E. MacAulay, Carlos E. Alvarez, Wan L. Lam

Published in: Cancer and Metastasis Reviews | Issue 1/2010

Login to get access

Abstract

Advances in high-throughput, genome-wide profiling technologies have allowed for an unprecedented view of the cancer genome landscape. Specifically, high-density microarrays and sequencing-based strategies have been widely utilized to identify genetic (such as gene dosage, allelic status, and mutations in gene sequence) and epigenetic (such as DNA methylation, histone modification, and microRNA) aberrations in cancer. Although the application of these profiling technologies in unidimensional analyses has been instrumental in cancer gene discovery, genes affected by low-frequency events are often overlooked. The integrative approach of analyzing parallel dimensions has enabled the identification of (a) genes that are often disrupted by multiple mechanisms but at low frequencies by any one mechanism and (b) pathways that are often disrupted at multiple components but at low frequencies at individual components. These benefits of using an integrative approach illustrate the concept that the whole is greater than the sum of its parts. As efforts have now turned toward parallel and integrative multidimensional approaches for studying the cancer genome landscape in hopes of obtaining a more insightful understanding of the key genes and pathways driving cancer cells, this review describes key findings disseminating from such high-throughput, integrative analyses, including contributions to our understanding of causative genetic events in cancer cell biology.
Literature
1.
Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., et al. (1998). High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genetics, 20(2), 207–211.PubMed
2.
Schrock, E., du Manoir, S., Veldman, T., Schoell, B., Wienberg, J., Ferguson-Smith, M. A., et al. (1996). Multicolor spectral karyotyping of human chromosomes. Science, 273(5274), 494–497.PubMed
3.
Drmanac, R., Sparks, A. B., Callow, M. J., Halpern, A. L., Burns, N. L., Kermani, B. G., et al. (2009). Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science, 327(5961), 78–81.PubMed
4.
Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J., Greenman, C. D., et al. (2009). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature.
5.
Pleasance, E. D., Stephens, P. J., O’Meara, S., McBride, D. J., Meynert, A., Jones, D., et al. (2009). A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature.
6.
Stephens, P. J., McBride, D. J., Lin, M. L., Varela, I., Pleasance, E. D., Simpson, J. T., et al. (2009). Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature, 462(7276), 1005–1010.PubMed
7.
Chari, R., Coe, B. P., Wedseltoft, C., Benetti, M., Wilson, I. M., Vucic, E. A., et al. (2008). SIGMA2: a system for the integrative genomic multi-dimensional analysis of cancer genomes, epigenomes, and transcriptomes. BMC Bioinformatics, 9, 422.PubMed
8.
von Eschenbach, A. C., & Buetow, K. (2007). Cancer informatics vision: caBIG. Cancer Informatics, 2, 22–24.
9.
Conde, L., Montaner, D., Burguet-Castell, J., Tarraga, J., Medina, I., Al-Shahrour, F., et al. (2007). ISACGH: a web-based environment for the analysis of Array CGH and gene expression which includes functional profiling. Nucleic Acids Research, 35(Web Server issue), W81–W85.PubMed
10.
La Rosa, P., Viara, E., Hupe, P., Pierron, G., Liva, S., Neuvial, P., et al. (2006). VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics, 22(17), 2066–2073.PubMed
11.
Horn, T., Arziman, Z., Berger, J., & Boutros, M. (2007). GenomeRNAi: a database for cell-based RNAi phenotypes. Nucleic Acids Research, 35, D492–D497.PubMed
12.
Gilsdorf, M., Horn, T., Arziman, Z., Pelz, O., Kiner, E., & Boutros, M. (2010). GenomeRNAi: a database for cell-based RNAi phenotypes. 2009 update. Nucleic Acids Research, 38, D448–D452.PubMed
13.
Shah, S. P., Morin, R. D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., et al. (2009). Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature, 461(7265), 809–813.PubMed
14.
Lister, R., Pelizzola, M., Dowen, R. H., Hawkins, R. D., Hon, G., Tonti-Filippini, J., et al. (2009). Human DNA methylomes at base resolution show widespread epigenomic differences. Nature, 462(7271), 315–322.PubMed
15.
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., et al. (2008). DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature, 456(7218), 66–72.PubMed
16.
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., et al. (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. New England Journal of Medicine, 361(11), 1058–1066.PubMed
17.
Wise, J. (2008). Consortium hopes to sequence genome of 1000 volunteers. BMJ, 336(7638), 237.PubMed
18.
The Cancer Genome Atlas Research Network. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455(7216), 1061–1068.
19.
Frazer, K. A., Ballinger, D. G., Cox, D. R., Hinds, D. A., Stuve, L. L., Gibbs, R. A., et al. (2007). A second generation human haplotype map of over 3.1 million SNPs. Nature, 449(7164), 851–861.PubMed
20.
Redon, R., Ishikawa, S., Fitch, K. R., Feuk, L., Perry, G. H., Andrews, T. D., et al. (2006). Global variation in copy number in the human genome. Nature, 444(7118), 444–454.PubMed
21.
Wong, K. K., deLeeuw, R. J., Dosanjh, N. S., Kimm, L. R., Cheng, Z., Horsman, D. E., et al. (2007). A comprehensive analysis of common copy-number variations in the human genome. American Journal of Human Genetics, 80(1), 91–104.PubMed
22.
Shames, D. S., Girard, L., Gao, B., Sato, M., Lewis, C. M., Shivapurkar, N., et al. (2006). A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Medicine, 3(12), e486.PubMed
23.
Sjoblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science, 314(5797), 268–274.PubMed
24.
Root, D. E., Hacohen, N., Hahn, W. C., Lander, E. S., & Sabatini, D. M. (2006). Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods, 3(9), 715–719.PubMed
25.
Bibikova, M., Lin, Z., Zhou, L., Chudin, E., Garcia, E. W., Wu, B., et al. (2006). High-throughput DNA methylation profiling using universal bead arrays. Genome Research, 16(3), 383–393.PubMed
26.
Weber, M., Davies, J. J., Wittig, D., Oakeley, E. J., Haase, M., Lam, W. L., et al. (2005). Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genetics, 37(8), 853–862.PubMed
27.
International HapMap Consortium. (2005). A haplotype map of the human genome. Nature, 437(7063), 1299–1320.
28.
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. (2005). MicroRNA expression profiles classify human cancers. Nature, 435(7043), 834–838.PubMed
29.
Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., et al. (2004). The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. British Journal of Cancer, 91(2), 355–358.PubMed
30.
Paddison, P. J., Silva, J. M., Conklin, D. S., Schlabach, M., Li, M., Aruleba, S., et al. (2004). A resource for large-scale RNA-interference-based screens in mammals. Nature, 428(6981), 427–431.PubMed
31.
Schlabach, M. R., Luo, J., Solimini, N. L., Hu, G., Xu, Q., Li, M. Z., et al. (2008). Cancer proliferation gene discovery through functional genomics. Science, 319(5863), 620–624.PubMed
32.
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., et al. (2004). A census of human cancer genes. Nature Reviews Cancer, 4(3), 177–183.PubMed
33.
Iafrate, A. J., Feuk, L., Rivera, M. N., Listewnik, M. L., Donahoe, P. K., Qi, Y., et al. (2004). Detection of large-scale variation in the human genome. Nature Genetics, 36(9), 949–951.PubMed
34.
Sebat, J., Lakshmi, B., Troge, J., Alexander, J., Young, J., Lundin, P., et al. (2004). Large-scale copy number polymorphism in the human genome. Science, 305(5683), 525–528.PubMed
35.
Ishkanian, A. S., Malloff, C. A., Watson, S. K., DeLeeuw, R. J., Chi, B., Coe, B. P., et al. (2004). A tiling resolution DNA microarray with complete coverage of the human genome. Nature Genetics, 36(3), 299–303.PubMed
36.
Bertone, P., Stolc, V., Royce, T. E., Rozowsky, J. S., Urban, A. E., Zhu, X., et al. (2004). Global identification of human transcribed sequences with genome tiling arrays. Science, 306(5705), 2242–2246.PubMed
37.
Hubbard, T., Barker, D., Birney, E., Cameron, G., Chen, Y., Clark, L., et al. (2002). The ensembl genome database project. Nucleic Acids Research, 30(1), 38–41.PubMed
38.
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., et al. (2002). The human genome browser at UCSC. Genome Research, 12(6), 996–1006.PubMed
39.
Oliphant, A., Barker, D. L., Stuelpnagel, J. R., & Chee M. S. (2002). BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques, Suppl:56–58, 60–51.
40.
Weinstein, I. B. (2002). Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science, 297(5578), 63–64.PubMed
41.
Weinstein, I. B., & Joe, A. (2008). Oncogene addiction. Cancer Research, 68(9), 3077–3080. discussion 3080.PubMed
42.
Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., et al. (2001). Initial sequencing and analysis of the human genome. Nature, 409(6822), 860–921.PubMed
43.
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., et al. (2001). The sequence of the human genome. Science, 291(5507), 1304–1351.PubMed
44.
Riggins, G. J., & Strausberg, R. L. (2001). Genome and genetic resources from the cancer genome anatomy project. Human Molecular Genetics, 10(7), 663–667.PubMed
45.
Strausberg, R. L., Buetow, K. H., Emmert-Buck, M. R., & Klausner, R. D. (2000). The cancer genome anatomy project: Building an annotated gene index. Trends in Genetics, 16(3), 103–106.PubMed
46.
Bayani, J. M., & Squire, J. A. (2002). Applications of SKY in cancer cytogenetics. Cancer Investigation, 20(3), 373–386.PubMed
47.
Kallioniemi, A., Kallioniemi, O. P., Sudar, D., Rutovitz, D., Gray, J. W., Waldman, F., et al. (1992). Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science, 258(5083), 818–821.PubMed
48.
Garnis, C., Buys, T. P., & Lam, W. L. (2004). Genetic alteration and gene expression modulation during cancer progression. Molecular Cancer, 3, 9.PubMed
49.
Gebhart, E. (2005). Genomic imbalances in human leukemia and lymphoma detected by comparative genomic hybridization (Review). International Journal of Oncology, 27(3), 593–606.PubMed
50.
Gebhart, E., & Liehr, T. (2000). Patterns of genomic imbalances in human solid tumors (Review). International Journal of Oncology, 16(2), 383–399.PubMed
51.
Cahill, D. P., Lengauer, C., Yu, J., Riggins, G. J., Willson, J. K., Markowitz, S. D., et al. (1998). Mutations of mitotic checkpoint genes in human cancers. Nature, 392(6673), 300–303.PubMed
52.
Fukasawa, K. (2005). Centrosome amplification, chromosome instability and cancer development. Cancer Letters, 230(1), 6–19.PubMed
53.
Lingle, W. L., Lukasiewicz, K., & Salisbury, J. L. (2005). Deregulation of the centrosome cycle and the origin of chromosomal instability in cancer. Advances in Experimental Medicine and Biology, 570, 393–421.PubMed
54.
Chin, K., de Solorzano, C. O., Knowles, D., Jones, A., Chou, W., Rodriguez, E. G., et al. (2004). In situ analyses of genome instability in breast cancer. Nature Genetics, 36(9), 984–988.PubMed
55.
O’Hagan, R. C., Chang, S., Maser, R. S., Mohan, R., Artandi, S. E., Chin, L., et al. (2002). Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell, 2(2), 149–155.PubMed
56.
Green, A. R. (1992). Transcription factors, translocations and haematological malignancies. Blood Reviews, 6(2), 118–124.PubMed
57.
Rowley, J. D. (2008). Chromosomal translocations: revisited yet again. Blood, 112(6), 2183–2189.PubMed
58.
Watson, S. K., deLeeuw, R. J., Horsman, D. E., Squire, J. A., & Lam, W. L. (2007). Cytogenetically balanced translocations are associated with focal copy number alterations. Human Genetics, 120(6), 795–805.PubMed
59.
Brenner, J. C., & Chinnaiyan, A. M. (2009). Translocations in epithelial cancers. Biochimica et Biophysica Acta, 1796(2), 201–215.PubMed
60.
Mani, R. S., Tomlins, S. A., Callahan, K., Ghosh, A., Nyati, M. K., Varambally, S., et al. (2009). Induced chromosomal proximity and gene fusions in prostate cancer. Science, 326(5957), 1230.PubMed
61.
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X. W., et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310(5748), 644–648.PubMed
62.
Dang, T. P., Gazdar, A. F., Virmani, A. K., Sepetavec, T., Hande, K. R., Minna, J. D., et al. (2000). Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. Journal of the National Cancer Institute, 92(16), 1355–1357.PubMed
63.
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448(7153), 561–566.PubMed
64.
Knutsen, T., Gobu, V., Knaus, R., Padilla-Nash, H., Augustus, M., Strausberg, R. L., et al. (2005). The interactive online SKY/M-FISH & CGH database and the Entrez cancer chromosomes search database: Linkage of chromosomal aberrations with the genome sequence. Genes, Chromosomes, and Cancer, 44(1), 52–64.PubMed
65.
Kapushesky, M., Emam, I., Holloway, E., Kurnosov, P., Zorin, A., Malone, J., et al. (2010). Gene expression atlas at the European bioinformatics institute. Nucleic Acids Research, 38, D690–D698.PubMed
66.
Li, L., Bum-Erdene, K., Baenziger, P. H., Rosen, J. J., Hemmert, J. R., Nellis, J. A., et al. (2010). BioDrugScreen: a computational drug design resource for ranking molecules docked to the human proteome. Nucleic Acids Research, 38, D765–D773.PubMed
67.
Forbes, S. A., Tang, G., Bindal, N., Bamford, S., Dawson, E., Cole, C., et al. (2010). COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Research, 38, D652–D657.PubMed
68.
Kato, K., Yamashita, R., Matoba, R., Monden, M., Noguchi, S., Takagi, T., et al. (2005). Cancer gene expression database (CGED): A database for gene expression profiling with accompanying clinical information of human cancer tissues. Nucleic Acids Research, 33, D533–D536.PubMed
69.
Li, H., He, Y., Ding, G., Wang, C., Xie, L., & Li, Y. (2010). dbDEPC: a database of differentially expressed proteins in human cancers. Nucleic Acids Research, 38, D658–D664.PubMed
70.
Brooksbank, C., Cameron, G., & Thornton, J. (2010). The European Bioinformatics Institute’s data resources. Nucleic Acids Research, 38, D17–25.PubMed
71.
Safran, M., Chalifa-Caspi, V., Shmueli, O., Olender, T., Lapidot, M., Rosen, N., et al. (2003). Human gene-centric databases at the Weizmann institute of science: GeneCards, UDB, CroW 21 and HORDE. Nucleic Acids Research, 31(1), 142–146.PubMed
72.
Zhang, Y., Lv, J., Liu, H., Zhu, J., Su, J., Wu, Q., et al. (2010). HHMD: the human histone modification database. Nucleic Acids Research, 38, D149–D154.PubMed
73.
Betel, D., Wilson, M., Gabow, A., Marks, D. S., & Sander, C. (2008). The microRNA.org resource: targets and expression. Nucleic Acids Research, 36, D149–D153.PubMed
74.
Jiang, Q., Wang, Y., Hao, Y., Juan, L., Teng, M., Zhang, X., et al. (2009). miR2Disease: A manually curated database for microRNA deregulation in human disease. Nucleic Acids Research, 37, D98–D104.PubMed
75.
Wang, X. (2008). miRDB: A microRNA target prediction and functional annotation database with a wiki interface. RNA, 14(6), 1012–1017.PubMed
76.
Alexiou, P., Vergoulis, T., Gleditzsch, M., Prekas, G., Dalamagas, T., Megraw, M., et al. (2010). miRGen 2.0: A database of microRNA genomic information and regulation. Nucleic Acids Research, 38, D137–D141.PubMed
77.
Sayers, E. W., Barrett, T., Benson, D. A., Bolton, E., Bryant, S. H., Canese, K., et al. (2010). Database resources of the National Center for Biotechnology Information. Nucleic Acids Research, 38, D5–D16.PubMed
78.
Barrett, T., Troup, D. B., Wilhite, S. E., Ledoux, P., Rudnev, D., Evangelista, C., et al. (2009). NCBI GEO: Archive for high-throughput functional genomic data. Nucleic Acids Research, 37, D885–D890.PubMed
79.
Rhodes, D. R., Kalyana-Sundaram, S., Mahavisno, V., Varambally, R., Yu, J., Briggs, B. B., et al. (2007). Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia, 9(2), 166–180.PubMed
80.
Baudis, M. (2007). Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer, 7, 226.PubMed
81.
Vizcaino, J. A., Cote, R., Reisinger, F., Barsnes, H., Foster, J. M., Rameseder, J., et al. (2010). The proteomics identifications database: 2010 update. Nucleic Acids Research, 38, D736–D742.PubMed
82.
Ren, Y., Gong, W., Zhou, H., Wang, Y., Xiao, F., & Li, T. (2009). siRecords: A database of mammalian RNAi experiments and efficacies. Nucleic Acids Research, 37, D146–D149.PubMed
83.
Chari, R., Lockwood, W. W., Coe, B. P., Chu, A., Macey, D., Thomson, A., et al. (2006). SIGMA: A system for integrative genomic microarray analysis of cancer genomes. BMC Genomics, 7, 324.PubMed
84.
Rhead, B., Karolchik, D., Kuhn, R. M., Hinrichs, A. S., Zweig, A. S., Fujita, P. A., et al. (2010). The UCSC genome browser database: Update 2010. Nucleic Acids Research, 38, D613–D619.PubMed
85.
Albertson, D. G., Collins, C., McCormick, F., & Gray, J. W. (2003). Chromosome aberrations in solid tumors. Nature Genetics, 34(4), 369–376.PubMed
86.
Coe, B. P., Ylstra, B., Carvalho, B., Meijer, G. A., Macaulay, C., & Lam, W. L. (2007). Resolving the resolution of array CGH. Genomics, 89(5), 647–653.PubMed
87.
Lockwood, W. W., Chari, R., Chi, B., & Lam, W. L. (2006). Recent advances in array comparative genomic hybridization technologies and their applications in human genetics. European Journal of Human Genetics, 14(2), 139–148.PubMed
88.
Pollack, J. R., Perou, C. M., Alizadeh, A. A., Eisen, M. B., Pergamenschikov, A., Williams, C. F., et al. (1999). Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nature Genetics, 23(1), 41–46.PubMed
89.
Almagro-Garcia, J., Manske, M., Carret, C., Campino, S., Auburn, S., Macinnis, B. L., et al. (2009). SnoopCGH: software for visualizing comparative genomic hybridization data. Bioinformatics, 25(20), 2732–2733.PubMed
90.
Chari, R., Lockwood, W. W., & Lam, W. L. (2007). Computational methods for the analysis of array comparative genomic hybridization. Cancer Information, 2, 48–58.
91.
Chi, B., DeLeeuw, R. J., Coe, B. P., MacAulay, C., & Lam, W. L. (2004). SeeGH—a software tool for visualization of whole genome array comparative genomic hybridization data. BMC Bioinformatics, 5, 13.PubMed
92.
Chi, B., deLeeuw, R. J., Coe, B. P., Ng, R. T., MacAulay, C., & Lam, W. L. (2008). MD-SeeGH: A platform for integrative analysis of multi-dimensional genomic data. BMC Bioinformatics, 9, 243.PubMed
93.
Venkatraman, E. S., & Olshen, A. B. (2007). A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics, 23(6), 657–663.PubMed
94.
Bignell, G. R., Huang, J., Greshock, J., Watt, S., Butler, A., West, S., et al. (2004). High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Research, 14(2), 287–295.PubMed
95.
Iacobucci, I., Storlazzi, C. T., Cilloni, D., Lonetti, A., Ottaviani, E., Soverini, S., et al. (2009). Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: On behalf of Gruppo Italiano Malattie Ematologiche dell’Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood, 114(10), 2159–2167.PubMed
96.
Niini, T., Lopez-Guerrero, J. A., Ninomiya, S., Guled, M., Hattinger, C. M., Michelacci, F., et al. (2009). Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone—an array comparative genomic hybridization study. Genes, Chromosomes, and Cancer, 49(2), 132–143.
97.
Selzer, R. R., Richmond, T. A., Pofahl, N. J., Green, R. D., Eis, P. S., Nair, P., et al. (2005). Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes, Chromosomes, and Cancer, 44(3), 305–319.PubMed
98.
Zhao, X., Li, C., Paez, J. G., Chin, K., Janne, P. A., Chen, T. H., et al. (2004). An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Research, 64(9), 3060–3071.PubMed
99.
Wang, T. L., Maierhofer, C., Speicher, M. R., Lengauer, C., Vogelstein, B., Kinzler, K. W., et al. (2002). Digital karyotyping. Proceedings of the National Academy of Sciences of the United States of America, 99(25), 16156–16161.PubMed
100.
Tuzun, E., Sharp, A. J., Bailey, J. A., Kaul, R., Morrison, V. A., Pertz, L. M., et al. (2005). Fine-scale structural variation of the human genome. Nature Genetics, 37(7), 727–732.PubMed
101.
Volik, S., Raphael, B. J., Huang, G., Stratton, M. R., Bignel, G., Murnane, J., et al. (2006). Decoding the fine-scale structure of a breast cancer genome and transcriptome. Genome Research, 16(3), 394–404.PubMed
102.
Volik, S., Zhao, S., Chin, K., Brebner, J. H., Herndon, D. R., Tao, Q., et al. (2003). End-sequence profiling: Sequence-based analysis of aberrant genomes. Proceedings of the National Academy of Sciences of the United States of America, 100(13), 7696–7701.PubMed
103.
McPherson, J. D. (2009). Next-generation gap. Nature Methods, 6(11 Suppl), S2–S5.PubMed
104.
Alkan, C., Kidd, J. M., Marques-Bonet, T., Aksay, G., Antonacci, F., Hormozdiari, F., et al. (2009). Personalized copy number and segmental duplication maps using next-generation sequencing. Nature Genetics, 41(10), 1061–1067.PubMed
105.
Conrad, D. F., Andrews, T. D., Carter, N. P., Hurles, M. E., & Pritchard, J. K. (2006). A high-resolution survey of deletion polymorphism in the human genome. Nature Genetics, 38(1), 75–81.PubMed
106.
Conrad, D. F., Pinto, D., Redon, R., Feuk, L., Gokcumen, O., Zhang, Y., et al. (2009). Origins and functional impact of copy number variation in the human genome. Nature. doi:10.​1038/​nature08516
107.
Fiegler, H., Redon, R., Andrews, D., Scott, C., Andrews, R., Carder, C., et al. (2006). Accurate and reliable high-throughput detection of copy number variation in the human genome. Genome Research, 16(12), 1566–1574.PubMed
108.
Jakobsson, M., Scholz, S. W., Scheet, P., Gibbs, J. R., VanLiere, J. M., Fung, H. C., et al. (2008). Genotype, haplotype and copy-number variation in worldwide human populations. Nature, 451(7181), 998–1003.PubMed
109.
Kidd, J. M., Cooper, G. M., Donahue, W. F., Hayden, H. S., Sampas, N., Graves, T., et al. (2008). Mapping and sequencing of structural variation from eight human genomes. Nature, 453(7191), 56–64.PubMed
110.
McCarroll, S. A., Kuruvilla, F. G., Korn, J. M., Cawley, S., Nemesh, J., Wysoker, A., et al. (2008). Integrated detection and population-genetic analysis of SNPs and copy number variation. Nature Genetics, 40(10), 1166–1174.PubMed
111.
Shaikh, T. H., Gai, X., Perin, J. C., Glessner, J. T., Xie, H., Murphy, K., et al. (2009). High-resolution mapping and analysis of copy number variations in the human genome: a data resource for clinical and research applications. Genome Research, 19(9), 1682–1690.PubMed
112.
Hastings, P. J., Ira, G., & Lupski, J. R. (2009). A microhomology-mediated break-induced replication model for the origin of human copy number variation. PLoS Genetics, 5(1), e1000327.PubMed
113.
Diskin, S. J., Hou, C., Glessner, J. T., Attiyeh, E. F., Laudenslager, M., Bosse, K., et al. (2009). Copy number variation at 1q21.1 associated with neuroblastoma. Nature, 459(7249), 987–991.PubMed
114.
Lockwood, W. W., Chari, R., Coe, B. P., Girard, L., Macaulay, C., Lam, S., et al. (2008). DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene, 27(33), 4615–4624.PubMed
115.
Myllykangas, S., Himberg, J., Bohling, T., Nagy, B., Hollmen, J., & Knuutila, S. (2006). DNA copy number amplification profiling of human neoplasms. Oncogene, 25(55), 7324–7332.PubMed
116.
Teschendorff, A. E., & Caldas, C. (2009). The breast cancer somatic ‘muta-ome’: tackling the complexity. Breast Cancer Research, 11(2), 301.PubMed
117.
Chin, S. F., Teschendorff, A. E., Marioni, J. C., Wang, Y., Barbosa-Morais, N. L., Thorne, N. P., et al. (2007). High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biology, 8(10), R215.PubMed
118.
Coe, B. P., Lockwood, W. W., Girard, L., Chari, R., Macaulay, C., Lam, S., et al. (2006). Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. British Journal of Cancer, 94(12), 1927–1935.PubMed
119.
Bass, A. J., Watanabe, H., Mermel, C. H., Yu, S., Perner, S., Verhaak, R. G., et al. (2009). SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics, 41(11), 1238–1242.PubMed
120.
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 436(7047), 117–122.PubMed
121.
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., et al. (2007). Characterizing the cancer genome in lung adenocarcinoma. Nature, 450(7171), 893–898.PubMed
122.
Kwei, K. A., Kim, Y. H., Girard, L., Kao, J., Pacyna-Gengelbach, M., Salari, K., et al. (2008). Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene, 27(25), 3635–3640.PubMed
123.
Plomin, R., Haworth, C. M., & Davis, O. S. (2009). Common disorders are quantitative traits. Nature Reviews Genetics, 10(12), 872–878.PubMed
124.
Savas, S., & Liu, G. (2009). Genetic variations as cancer prognostic markers: Review and update. Human Mutation, 30(10), 1369–1377.PubMed
125.
Ansorge, W. J. (2009). Next-generation DNA sequencing techniques. New Biotechnology, 25(4), 195–203.PubMed
126.
Shah, S. P., Kobel, M., Senz, J., Morin, R. D., Clarke, B. A., Wiegand, K. C., et al. (2009). Mutation of FOXL2 in granulosa-cell tumors of the ovary. New England Journal of Medicine, 360(26), 2719–2729.PubMed
127.
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature, 446(7132), 153–158.PubMed
128.
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009). The cancer genome. Nature, 458(7239), 719–724.PubMed
129.
Cavenee, W. K., Hansen, M. F., Nordenskjold, M., Kock, E., Maumenee, I., Squire, J. A., et al. (1985). Genetic origin of mutations predisposing to retinoblastoma. Science, 228(4698), 501–503.PubMed
130.
Knudson, A. G., Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America, 68(4), 820–823.PubMed
131.
Benz, C. C., Fedele, V., Xu, F., Ylstra, B., Ginzinger, D., Yu, M., et al. (2006). Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers. Genes, Chromosomes, and Cancer, 45(11), 983–994.PubMed
132.
LaFramboise, T., Weir, B. A., Zhao, X., Beroukhim, R., Li, C., Harrington, D., et al. (2005). Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol, 1(6), e65.PubMed
133.
Melcher, R., Al-Taie, O., Kudlich, T., Hartmann, E., Maisch, S., Steinlein, C., et al. (2007). SNP-Array genotyping and spectral karyotyping reveal uniparental disomy as early mutational event in MSS- and MSI-colorectal cancer cell lines. Cytogenetic and Genome Research, 118(2–4), 214–221.PubMed
134.
Nomura, M., Shigematsu, H., Li, L., Suzuki, M., Takahashi, T., Estess, P., et al. (2007). Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Medicine, 4(4), e125.PubMed
135.
Sholl, L. M., Yeap, B. Y., Iafrate, A. J., Holmes-Tisch, A. J., Chou, Y. P., Wu, M. T., et al. (2009). Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Research, 69(21), 8341–8348.PubMed
136.
Soh, J., Okumura, N., Lockwood, W. W., Yamamoto, H., Shigematsu, H., Zhang, W., et al. (2009). Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS ONE, 4(10), e7464.PubMed
137.
Bacolod, M. D., Schemmann, G. S., Giardina, S. F., Paty, P., Notterman, D. A., & Barany, F. (2009). Emerging paradigms in cancer genetics: some important findings from high-density single nucleotide polymorphism array studies. Cancer Research, 69(3), 723–727.PubMed
138.
Robinson, W. P. (2000). Mechanisms leading to uniparental disomy and their clinical consequences. Bioessays, 22(5), 452–459.PubMed
139.
Tuna, M., Knuutila, S., & Mills, G. B. (2009). Uniparental disomy in cancer. Trends in Molecular Medicine, 15(3), 120–128.PubMed
140.
Zhu, X., Dunn, J. M., Goddard, A. D., Squire, J. A., Becker, A., Phillips, R. A., et al. (1992). Mechanisms of loss of heterozygosity in retinoblastoma. Cytogenetics and Cell Genetics, 59(4), 248–252.PubMed
141.
Gondek, L. P., Dunbar, A. J., Szpurka, H., McDevitt, M. A., & Maciejewski, J. P. (2007). SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS ONE, 2(11), e1225.PubMed
142.
Tiu, R. V., Gondek, L. P., O’Keefe, C. L., Huh, J., Sekeres, M. A., Elson, P., et al. (2009). New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. Journal of Clinical Oncology, 27(31), 5219–5226.PubMed
143.
Yamamoto, G., Nannya, Y., Kato, M., Sanada, M., Levine, R. L., Kawamata, N., et al. (2007). Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. American Journal of Human Genetics, 81(1), 114–126.PubMed
144.
Darbary, H. K., Dutt, S. S., Sait, S. J., Nowak, N. J., Heinaman, R. E., Stoler, D. L., et al. (2009). Uniparentalism in sporadic colorectal cancer is independent of imprint status, and coordinate for chromosomes 14 and 18. Cancer Genetics and Cytogenetics, 189(2), 77–86.PubMed
145.
Grand, F. H., Hidalgo-Curtis, C. E., Ernst, T., Zoi, K., Zoi, C., McGuire, C., et al. (2009). Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood, 113(24), 6182–6192.PubMed
146.
Gupta, M., Raghavan, M., Gale, R. E., Chelala, C., Allen, C., Molloy, G., et al. (2008). Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes, Chromosomes, and Cancer, 47(9), 729–739.PubMed
147.
Kawamata, N., Ogawa, S., Gueller, S., Ross, S. H., Huynh, T., Chen, J., et al. (2009). Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. Experimental Hematology, 37(8), 937–946.PubMed
148.
Makishima, H., Cazzolli, H., Szpurka, H., Dunbar, A., Tiu, R., Huh, J., et al. (2009). Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. Journal of Clinical Oncology, 27(36), 6109–6116.PubMed
149.
Walter, M. J., Payton, J. E., Ries, R. E., Shannon, W. D., Deshmukh, H., Zhao, Y., et al. (2009). Acquired copy number alterations in adult acute myeloid leukemia genomes. Proceedings of the National Academy of Sciences of the United States of America, 106(31), 12950–12955.PubMed
150.
Yin, D., Ogawa, S., Kawamata, N., Tunici, P., Finocchiaro, G., Eoli, M., et al. (2009). High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res, 7(5), 665–677.PubMed
151.
Purdie, K. J., Lambert, S. R., Teh, M. T., Chaplin, T., Molloy, G., Raghavan, M., et al. (2007). Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. Genes, Chromosomes, and Cancer, 46(7), 661–669.PubMed
152.
Akagi, T., Ito, T., Kato, M., Jin, Z., Cheng, Y., Kan, T., et al. (2009). Chromosomal abnormalities and novel disease-related regions in progression from Barrett’s esophagus to esophageal adenocarcinoma. International Journal of Cancer, 125(10), 2349–2359.
153.
Andersen, C. L., Wiuf, C., Kruhoffer, M., Korsgaard, M., Laurberg, S., & Orntoft, T. F. (2007). Frequent occurrence of uniparental disomy in colorectal cancer. Carcinogenesis, 28(1), 38–48.PubMed
154.
Kerkel, K., Spadola, A., Yuan, E., Kosek, J., Jiang, L., Hod, E., et al. (2008). Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nature Genetics, 40(7), 904–908.PubMed
155.
Jones, P. A., & Baylin, S. B. (2007). The epigenomics of cancer. Cell, 128(4), 683–692.PubMed
156.
Esteller, M. (2008). Epigenetics in cancer. New England Journal of Medicine, 358(11), 1148–1159.PubMed
157.
Feinberg, A. P. (2007). Phenotypic plasticity and the epigenetics of human disease. Nature, 447(7143), 433–440.PubMed
158.
Vucic, E. A., Brown, C. J., & Lam, W. L. (2008). Epigenetics of cancer progression. Pharmacogenomics, 9(2), 215–234.PubMed
159.
Feinberg, A. P., Gehrke, C. W., Kuo, K. C., & Ehrlich, M. (1988). Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Research, 48(5), 1159–1161.PubMed
160.
Feinberg, A. P., & Tycko, B. (2004). The history of cancer epigenetics. Nature Reviews Cancer, 4(2), 143–153.PubMed
161.
Lo, P. K., & Sukumar, S. (2008). Epigenomics and breast cancer. Pharmacogenomics, 9(12), 1879–1902.PubMed
162.
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J. P. (1999). CpG island methylator phenotype in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 96(15), 8681–8686.PubMed
163.
Issa, J. P. (2004). CpG island methylator phenotype in cancer. Nature Reviews Cancer, 4(12), 988–993.PubMed
164.
Tanemura, A., Terando, A. M., Sim, M. S., van Hoesel, A. Q., de Maat, M. F., Morton, D. L., et al. (2009). CpG island methylator phenotype predicts progression of malignant melanoma. Clinical Cancer Research, 15(5), 1801–1807.PubMed
165.
Dai, Z., Lakshmanan, R. R., Zhu, W. G., Smiraglia, D. J., Rush, L. J., Fruhwald, M. C., et al. (2001). Global methylation profiling of lung cancer identifies novel methylated genes. Neoplasia, 3(4), 314–323.PubMed
166.
Takai, D., Yagi, Y., Wakazono, K., Ohishi, N., Morita, Y., Sugimura, T., et al. (2001). Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis. Oncogene, 20(51), 7505–7513.PubMed
167.
Hu, M., Yao, J., Cai, L., Bachman, K. E., van den Brule, F., Velculescu, V., et al. (2005). Distinct epigenetic changes in the stromal cells of breast cancers. Nature Genetics, 37(8), 899–905.PubMed
168.
Irizarry, R. A., Ladd-Acosta, C., Carvalho, B., Wu, H., Brandenburg, S. A., Jeddeloh, J. A., et al. (2008). Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Research, 18(5), 780–790.PubMed
169.
Yan, P. S., Chen, C. M., Shi, H., Rahmatpanah, F., Wei, S. H., Caldwell, C. W., et al. (2001). Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Research, 61(23), 8375–8380.PubMed
170.
Yamamoto, F., & Yamamoto, M. (2004). A DNA microarray-based methylation-sensitive (MS)-AFLP hybridization method for genetic and epigenetic analyses. Mol Genet Genomics, 271(6), 678–686.PubMed
171.
Omura, N., Li, C. P., Li, A., Hong, S. M., Walter, K., Jimeno, A., et al. (2008). Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther, 7(7), 1146–1156.PubMed
172.
Trinh, B. N., Long, T. I., & Laird, P. W. (2001). DNA methylation analysis by MethyLight technology. Methods, 25(4), 456–462.PubMed
173.
Fan, J. B., Gunderson, K. L., Bibikova, M., Yeakley, J. M., Chen, J., Wickham Garcia, E., et al. (2006). Illumina universal bead arrays. Methods in Enzymology, 410, 57–73.PubMed
174.
Houshdaran, S., Cortessis, V. K., Siegmund, K., Yang, A., Laird, P. W., & Sokol, R. Z. (2007). Widespread epigenetic abnormalities suggest a broad DNA methylation erasure defect in abnormal human sperm. PLoS ONE, 2(12), e1289.PubMed
175.
Houseman, E. A., Christensen, B. C., Karagas, M. R., Wrensch, M. R., Nelson, H. H., Wiemels, J. L., et al. (2009). Copy number variation has little impact on bead-array-based measures of DNA methylation. Bioinformatics, 25(16), 1999–2005.PubMed
176.
Breton, C. V., Byun, H. M., Wenten, M., Pan, F., Yang, A., & Gilliland, F. D. (2009). Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. American Journal of Respiratory and Critical Care Medicine, 180(5), 462–467.PubMed
177.
Taylor, K. H., Pena-Hernandez, K. E., Davis, J. W., Arthur, G. L., Duff, D. J., Shi, H., et al. (2007). Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Research, 67(6), 2617–2625.PubMed
178.
Weber, M., Hellmann, I., Stadler, M. B., Ramos, L., Paabo, S., Rebhan, M., et al. (2007). Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nature Genetics, 39(4), 457–466.PubMed
179.
Rauch, T., & Pfeifer, G. P. (2005). Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Laboratory Investigation, 85(9), 1172–1180.PubMed
180.
Jacinto, F. V., Ballestar, E., Ropero, S., & Esteller, M. (2007). Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. Cancer Research, 67(24), 11481–11486.PubMed
181.
Ballestar, E., Paz, M. F., Valle, L., Wei, S., Fraga, M. F., Espada, J., et al. (2003). Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO Journal, 22(23), 6335–6345.PubMed
182.
Serre, D., Lee, B. H., & Ting, A. H. (2009). MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Research. doi:10.​1093/​nar/​gkp992.
183.
Down, T. A., Rakyan, V. K., Turner, D. J., Flicek, P., Li, H., Kulesha, E., et al. (2008). A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nature Biotechnology, 26(7), 779–785.PubMed
184.
Thu, K. L., Pikor, L. A., Kennett, J. Y., Alvarez, C. E., & Lam, W. L. (2009). Methylation analysis by DNA immunoprecipitation. Journal of Cellular Physiology, 222(3), 522–531.
185.
Pelizzola, M., Koga, Y., Urban, A. E., Krauthammer, M., Weissman, S., Halaban, R., et al. (2008). MEDME: an experimental and analytical methodology for the estimation of DNA methylation levels based on microarray derived MeDIP-enrichment. Genome Research, 18(10), 1652–1659.PubMed
186.
Yamashita, S., Hosoya, K., Gyobu, K., Takeshima, H., & Ushijima, T. (2009). Development of a novel output value for quantitative assessment in methylated DNA immunoprecipitation-CpG island microarray analysis. DNA Research, 16(5), 275–286.PubMed
187.
Irizarry, R. A., Ladd-Acosta, C., Wen, B., Wu, Z., Montano, C., Onyango, P., et al. (2009). The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nature Genetics, 41(2), 178–186.PubMed
188.
Lorincz, M. C., Dickerson, D. R., Schmitt, M., & Groudine, M. (2004). Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nature Structural & Molecular Biology, 11(11), 1068–1075.
189.
Frigola, J., Song, J., Stirzaker, C., Hinshelwood, R. A., Peinado, M. A., & Clark, S. J. (2006). Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nature Genetics, 38(5), 540–549.PubMed
190.
Zhong, S., Fields, C. R., Su, N., Pan, Y. X., & Robertson, K. D. (2007). Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene, 26(18), 2621–2634.PubMed
191.
Lister, R., & Ecker, J. R. (2009). Finding the fifth base: genome-wide sequencing of cytosine methylation. Genome Research, 19(6), 959–966.PubMed
192.
Byun, H. M., Siegmund, K. D., Pan, F., Weisenberger, D. J., Kanel, G., Laird, P. W., et al. (2009). Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue- and individual-specific DNA methylation patterns. Human Molecular Genetics, 18(24), 4808–4817.PubMed
193.
Fraga, M. F., Ballestar, E., Paz, M. F., Ropero, S., Setien, F., Ballestar, M. L., et al. (2005). Epigenetic differences arise during the lifetime of monozygotic twins. Proceedings of the National Academy of Sciences of the United States of America, 102(30), 10604–10609.PubMed
194.
Deng, J., Shoemaker, R., Xie, B., Gore, A., LeProust, E. M., Antosiewicz-Bourget, J., et al. (2009). Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nature Biotechnology, 27(4), 353–360.PubMed
195.
Costello, J. F., Fruhwald, M. C., Smiraglia, D. J., Rush, L. J., Robertson, G. P., Gao, X., et al. (2000). Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genetics, 24(2), 132–138.PubMed
196.
Gama-Sosa, M. A., Midgett, R. M., Slagel, V. A., Githens, S., Kuo, K. C., Gehrke, C. W., et al. (1983). Tissue-specific differences in DNA methylation in various mammals. Biochimica et Biophysica Acta, 740(2), 212–219.PubMed
197.
Richardson, B. (2003). Impact of aging on DNA methylation. Ageing Research Reviews, 2(3), 245–261.PubMed
198.
Eckhardt, F., Beck, S., Gut, I. G., & Berlin, K. (2004). Future potential of the human epigenome project. Expert Review of Molecular Diagnostics, 4(5), 609–618.PubMed
199.
Kohda, M., Hoshiya, H., Katoh, M., Tanaka, I., Masuda, R., Takemura, T., et al. (2001). Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Molecular Carcinogenesis, 31(4), 184–191.PubMed
200.
Kondo, M., Suzuki, H., Ueda, R., Osada, H., Takagi, K., & Takahashi, T. (1995). Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene, 10(6), 1193–1198.PubMed
201.
Rainier, S., Johnson, L. A., Dobry, C. J., Ping, A. J., Grundy, P. E., & Feinberg, A. P. (1993). Relaxation of imprinted genes in human cancer. Nature, 362(6422), 747–749.PubMed
202.
Pal, N., Wadey, R. B., Buckle, B., Yeomans, E., Pritchard, J., & Cowell, J. K. (1990). Preferential loss of maternal alleles in sporadic Wilms’ tumour. Oncogene, 5(11), 1665–1668.PubMed
203.
Schroeder, W. T., Chao, L. Y., Dao, D. D., Strong, L. C., Pathak, S., Riccardi, V., et al. (1987). Nonrandom loss of maternal chromosome 11 alleles in Wilms tumors. American Journal of Human Genetics, 40(5), 413–420.PubMed
204.
Scrable, H., Cavenee, W., Ghavimi, F., Lovell, M., Morgan, K., & Sapienza, C. (1989). A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proceedings of the National Academy of Sciences of the United States of America, 86(19), 7480–7484.PubMed
205.
Gaudet, F., Hodgson, J. G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J. W., et al. (2003). Induction of tumors in mice by genomic hypomethylation. Science, 300(5618), 489–492.PubMed
206.
Rizwana, R., & Hahn, P. J. (1999). CpG methylation reduces genomic instability. Journal of Cell Science, 112(Pt 24), 4513–4519.PubMed
207.
Daskalos, A., Nikolaidis, G., Xinarianos, G., Savvari, P., Cassidy, A., Zakopoulou, R., et al. (2009). Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. International Journal of Cancer, 124(1), 81–87.
208.
Walsh, C. P., Chaillet, J. R., & Bestor, T. H. (1998). Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nature Genetics, 20(2), 116–117.PubMed
209.
Chalitchagorn, K., Shuangshoti, S., Hourpai, N., Kongruttanachok, N., Tangkijvanich, P., Thong-ngam, D., et al. (2004). Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene, 23(54), 8841–8846.PubMed
210.
Rauch, T. A., Zhong, X., Wu, X., Wang, M., Kernstine, K. H., Wang, Z., et al. (2008). High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 105(1), 252–257.PubMed
211.
Groudine, M., Eisenman, R., & Weintraub, H. (1981). Chromatin structure of endogenous retroviral genes and activation by an inhibitor of DNA methylation. Nature, 292(5821), 311–317.PubMed
212.
Wilson, I. M., Davies, J. J., Weber, M., Brown, C. J., Alvarez, C. E., MacAulay, C., et al. (2006). Epigenomics: mapping the methylome. Cell Cycle, 5(2), 155–158.PubMed
213.
Cadieux, B., Ching, T. T., VandenBerg, S. R., & Costello, J. F. (2006). Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Research, 66(17), 8469–8476.PubMed
214.
Zabarovsky, E. R., Lerman, M. I., & Minna, J. D. (2002). Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene, 21(45), 6915–6935.PubMed
215.
Belinsky, S. A., Palmisano, W. A., Gilliland, F. D., Crooks, L. A., Divine, K. K., Winters, S. A., et al. (2002). Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Research, 62(8), 2370–2377.PubMed
216.
Palmisano, W. A., Divine, K. K., Saccomanno, G., Gilliland, F. D., Baylin, S. B., Herman, J. G., et al. (2000). Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Research, 60(21), 5954–5958.PubMed
217.
Belinsky, S. A. (2004). Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Reviews Cancer, 4(9), 707–717.PubMed
218.
Tessema, M., Willink, R., Do, K., Yu, Y. Y., Yu, W., Machida, E. O., et al. (2008). Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Research, 68(6), 1707–1714.PubMed
219.
Heintzman, N. D., Hon, G. C., Hawkins, R. D., Kheradpour, P., Stark, A., Harp, L. F., et al. (2009). Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature, 459(7243), 108–112.PubMed
220.
Komashko, V. M., Acevedo, L. G., Squazzo, S. L., Iyengar, S. S., Rabinovich, A., O’Geen, H., et al. (2008). Using ChIP-chip technology to reveal common principles of transcriptional repression in normal and cancer cells. Genome Research, 18(4), 521–532.PubMed
221.
Ke, X. S., Qu, Y., Rostad, K., Li, W. C., Lin, B., Halvorsen, O. J., et al. (2009). Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS ONE, 4(3), e4687.PubMed
222.
Kondo, Y., Shen, L., Cheng, A. S., Ahmed, S., Boumber, Y., Charo, C., et al. (2008). Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nature Genetics, 40(6), 741–750.PubMed
223.
Yu, J., Rhodes, D. R., Tomlins, S. A., Cao, X., Chen, G., Mehra, R., et al. (2007). A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Research, 67(22), 10657–10663.PubMed
224.
Wu, J., Wang, S. H., Potter, D., Liu, J. C., Smith, L. T., Wu, Y. Z., et al. (2007). Diverse histone modifications on histone 3 lysine 9 and their relation to DNA methylation in specifying gene silencing. BMC Genomics, 8, 131.PubMed
225.
Krivtsov, A. V., Feng, Z., Lemieux, M. E., Faber, J., Vempati, S., Sinha, A. U., et al. (2008). H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell, 14(5), 355–368.PubMed
226.
Lin, B., Wang, J., Hong, X., Yan, X., Hwang, D., Cho, J. H., et al. (2009). Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS ONE, 4(8), e6589.PubMed
227.
Fullwood, M. J., Liu, M. H., Pan, Y. F., Liu, J., Xu, H., Mohamed, Y. B., et al. (2009). An oestrogen-receptor-alpha-bound human chromatin interactome. Nature, 462(7269), 58–64.PubMed
228.
Coe, B. P., Chari, R., Lockwood, W. W., & Lam, W. L. (2008). Evolving strategies for global gene expression analysis of cancer. Journal of Cellular Physiology, 217(3), 590–597.PubMed
229.
Liang, P., & Pardee, A. B. (2003). Analysing differential gene expression in cancer. Nature Reviews Cancer, 3(11), 869–876.PubMed
230.
Nevins, J. R., & Potti, A. (2007). Mining gene expression profiles: Expression signatures as cancer phenotypes. Nature Reviews Genetics, 8(8), 601–609.PubMed
231.
Pollack, J. R., Sorlie, T., Perou, C. M., Rees, C. A., Jeffrey, S. S., Lonning, P. E., et al. (2002). Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proceedings of the National Academy of Sciences of the United States of America, 99(20), 12963–12968.PubMed
232.
Heidenblad, M., Lindgren, D., Veltman, J. A., Jonson, T., Mahlamaki, E. H., Gorunova, L., et al. (2005). Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications. Oncogene, 24(10), 1794–1801.PubMed
233.
Hyman, E., Kauraniemi, P., Hautaniemi, S., Wolf, M., Mousses, S., Rozenblum, E., et al. (2002). Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Research, 62(21), 6240–6245.PubMed
234.
Wolf, M., Mousses, S., Hautaniemi, S., Karhu, R., Huusko, P., Allinen, M., et al. (2004). High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: Impact of copy number on gene expression. Neoplasia, 6(3), 240–247.PubMed
235.
Adelaide, J., Finetti, P., Bekhouche, I., Repellini, L., Geneix, J., Sircoulomb, F., et al. (2007). Integrated profiling of basal and luminal breast cancers. Cancer Research, 67(24), 11565–11575.PubMed
236.
Broet, P., Camilleri-Broet, S., Zhang, S., Alifano, M., Bangarusamy, D., Battistella, M., et al. (2009). Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: Implications for chemotherapy selection. Cancer Research, 69(3), 1055–1062.PubMed
237.
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W. L., et al. (2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell, 10(6), 529–541.PubMed
238.
Natrajan, R., Weigelt, B., Mackay, A., Geyer, F. C., Grigoriadis, A., Tan, D. S., et al. (2009). An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Research and Treatment. doi:s00280-009-1073-y/​s10549-009-0501-3.
239.
Deng, S., Calin, G. A., Croce, C. M., Coukos, G., & Zhang, L. (2008). Mechanisms of microRNA deregulation in human cancer. Cell Cycle, 7(17), 2643–2646.PubMed
240.
Kuo, K. T., Guan, B., Feng, Y., Mao, T. L., Chen, X., Jinawath, N., et al. (2009). Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Research, 69(9), 4036–4042.PubMed
241.
Lionetti, M., Agnelli, L., Mosca, L., Fabris, S., Andronache, A., Todoerti, K., et al. (2009). Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes, Chromosomes, and Cancer, 48(6), 521–531.PubMed
242.
Starczynowski, D. T., Kuchenbauer, F., Argiropoulos, B., Sung, S., Morin, R., Muranyi, A., et al. (2009). Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Natural Medicines, 16, 49–58.
243.
Zhang, L., Volinia, S., Bonome, T., Calin, G. A., Greshock, J., Yang, N., et al. (2008). Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 105(19), 7004–7009.PubMed
244.
Calin, G. A., & Croce, C. M. (2006). MicroRNA signatures in human cancers. Nature Reviews Cancer, 6(11), 857–866.PubMed
245.
Nicoloso, M. S., Spizzo, R., Shimizu, M., Rossi, S., & Calin, G. A. (2009). MicroRNAs—the micro steering wheel of tumour metastases. Nature Reviews Cancer, 9(4), 293–302.PubMed
246.
Wolf, N. G., Farver, C., Abdul-Karim, F. W., & Schwartz, S. (2003). Analysis of microsatellite instability and X-inactivation in ovarian borderline tumors lacking numerical abnormalities by comparative genomic hybridization. Cancer Genetics and Cytogenetics, 145(2), 133–138.PubMed
247.
Olson, P., Lu, J., Zhang, H., Shai, A., Chun, M. G., Wang, Y., et al. (2009). MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes and Development, 23(18), 2152–2165.PubMed
248.
Garzon, R., Calin, G. A., & Croce, C. M. (2009). MicroRNAs in cancer. Annual Review of Medicine, 60, 167–179.PubMed
249.
Lujambio, A., & Esteller, M. (2009). How epigenetics can explain human metastasis: A new role for microRNAs. Cell Cycle, 8(3), 377–382.PubMed
250.
Iorio, M. V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., et al. (2007). MicroRNA signatures in human ovarian cancer. Cancer Research, 67(18), 8699–8707.PubMed
251.
Lujambio, A., & Esteller, M. (2007). CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle, 6(12), 1455–1459.PubMed
252.
Lujambio, A., Ropero, S., Ballestar, E., Fraga, M. F., Cerrato, C., Setien, F., et al. (2007). Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Research, 67(4), 1424–1429.PubMed
253.
Guil, S., & Esteller, M. (2009). DNA methylomes, histone codes and miRNAs: Tying it all together. International Journal of Biochemistry and Cell Biology, 41(1), 87–95.PubMed
254.
Sadikovic, B., Yoshimoto, M., Chilton-MacNeill, S., Thorner, P., Squire, J. A., & Zielenska, M. (2009). Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Human Molecular Genetics, 18(11), 1962–1975.PubMed
255.
Adamovic, T., Trosso, F., Roshani, L., Andersson, L., Petersen, G., Rajaei, S., et al. (2005). Oncogene amplification in the proximal part of chromosome 6 in rat endometrial adenocarcinoma as revealed by combined BAC/PAC FISH, chromosome painting, zoo-FISH, and allelotyping. Genes, Chromosomes, and Cancer, 44(2), 139–153.PubMed
256.
Ferrandina, G., Mey, V., Nannizzi, S., Ricciardi, S., Petrillo, M., Ferlini, C., et al. (2009). Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Cancer Chemotherapy and Pharmacology. doi:s00280-009-1073-y/​s00280-009-1073-y.
257.
Fernandez-Ranvier, G. G., Weng, J., Yeh, R. F., Khanafshar, E., Suh, I., Barker, C., et al. (2008). Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Archives of Surgery, 143(9), 841–846. discussion 846.PubMed
258.
Segditsas, S., Sieber, O., Deheragoda, M., East, P., Rowan, A., Jeffery, R., et al. (2008). Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice. Human Molecular Genetics, 17(24), 3864–3875.PubMed
259.
Joshi, M. D., Ahmad, R., Yin, L., Raina, D., Rajabi, H., Bubley, G., et al. (2009). MUC1 oncoprotein is a druggable target in human prostate cancer cells. Molecular Cancer Therapeutics, 8(11), 3056–3065.PubMed
260.
Khodarev, N. N., Pitroda, S. P., Beckett, M. A., MacDermed, D. M., Huang, L., Kufe, D. W., et al. (2009). MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Research, 69(7), 2833–2837.PubMed
261.
Senapati, S., Das, S., & Batra, S. K. (2009). Mucin-interacting proteins: from function to therapeutics. Trends in Biochemical Sciences.
262.
Buys, T. P., Aviel-Ronen, S., Waddell, T. K., Lam, W. L., & Tsao, M. S. (2009). Defining genomic alteration boundaries for a combined small cell and non-small cell lung carcinoma. Journal of Thoracic Oncology, 4(2), 227–239.PubMed
263.
Brommesson, S., Jonsson, G., Strand, C., Grabau, D., Malmstrom, P., Ringner, M., et al. (2008). Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs. BMC Clinical Pathology, 8, 6.PubMed
264.
Kawanishi, H., Takahashi, T., Ito, M., Matsui, Y., Watanabe, J., Ito, N., et al. (2007). Genetic analysis of multifocal superficial urothelial cancers by array-based comparative genomic hybridisation. British Journal of Cancer, 97(2), 260–266.PubMed
265.
Mhawech-Fauceglia, P., Rai, H., Nowak, N., Cheney, R. T., Rodabaugh, K., Lele, S., et al. (2008). The use of array-based comparative genomic hybridization (a-CGH) to distinguish metastatic from primary synchronous carcinomas of the ovary and the uterus. Histopathology, 53(4), 490–495.PubMed
266.
Nakano, H., Soda, H., Nakamura, Y., Uchida, K., Takasu, M., Nakatomi, K., et al. (2007). Different epidermal growth factor receptor gene mutations in a patient with 2 synchronous lung cancers. Clinical Lung Cancer, 8(9), 562–564.PubMed
267.
Ryoo, B. Y., Na, I. I., Yang, S. H., Koh, J. S., Kim, C. H., & Lee, J. C. (2006). Synchronous multiple primary lung cancers with different response to gefitinib. Lung Cancer, 53(2), 245–248.PubMed
268.
Speel, E. J., van de Wouw, A. J., Claessen, S. M., Haesevoets, A., Hopman, A. H., van der Wurff, A. A., et al. (2008). Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma. International Journal of Cancer, 123(6), 1292–1300.
269.
Wa, C. V., DeVries, S., Chen, Y. Y., Waldman, F. M., & Hwang, E. S. (2005). Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors. Modern Pathology, 18(4), 591–597.PubMed
270.
Agelopoulos, K., Tidow, N., Korsching, E., Voss, R., Hinrichs, B., Brandt, B., et al. (2003). Molecular cytogenetic investigations of synchronous bilateral breast cancer. Journal of Clinical Pathology, 56(9), 660–665.PubMed
271.
Whitehurst, A. W., Bodemann, B. O., Cardenas, J., Ferguson, D., Girard, L., Peyton, M., et al. (2007). Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature, 446(7137), 815–819.PubMed
272.
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., et al. (2009). Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 462(7269), 108–112.PubMed
273.
Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., et al. (2004). A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature, 428(6981), 431–437.PubMed
274.
Gobeil, S., Zhu, X., Doillon, C. J., & Green, M. R. (2008). A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene. Genes and Development, 22(21), 2932–2940.PubMed
275.
Luo, B., Cheung, H. W., Subramanian, A., Sharifnia, T., Okamoto, M., Yang, X., et al. (2008). Highly parallel identification of essential genes in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 105(51), 20380–20385.PubMed
276.
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., et al. (2009). A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell, 137(5), 835–848.PubMed
277.
Moffat, J., Grueneberg, D. A., Yang, X., Kim, S. Y., Kloepfer, A. M., Hinkle, G., et al. (2006). A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell, 124(6), 1283–1298.PubMed
278.
Scholl, C., Frohling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., et al. (2009). Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell, 137(5), 821–834.PubMed
279.
Silva, J. M., Marran, K., Parker, J. S., Silva, J., Golding, M., Schlabach, M. R., et al. (2008). Profiling essential genes in human mammary cells by multiplex RNAi screening. Science, 319(5863), 617–620.PubMed
280.
Apweiler, R., Aslanidis, C., Deufel, T., Gerstner, A., Hansen, J., Hochstrasser, D., et al. (2009). Approaching clinical proteomics: current state and future fields of application in cellular proteomics. Cytometry A, 75(10), 816–832.PubMed
281.
Apweiler, R., Aslanidis, C., Deufel, T., Gerstner, A., Hansen, J., Hochstrasser, D., et al. (2009). Approaching clinical proteomics: Current state and future fields of application in fluid proteomics. Clinical Chemistry and Laboratory Medicine, 47(6), 724–744.PubMed
282.
Peng, X. Q., Wang, F., Geng, X., & Zhang, W. M. (2009). Current advances in tumor proteomics and candidate biomarkers for hepatic cancer. Expert Review of Proteomics, 6(5), 551–561.PubMed
283.
Tainsky, M. A. (2009). Genomic and proteomic biomarkers for cancer: A multitude of opportunities. Biochimica et Biophysica Acta, 1796(2), 176–193.PubMed
284.
Zamo, A., & Cecconi, D. (2009). Proteomic analysis of lymphoid and haematopoietic neoplasms: There’s more than biomarker discovery. J Proteomics.
285.
Griffin, J. L., & Kauppinen, R. A. (2007). A metabolomics perspective of human brain tumours. FEBS Journal, 274(5), 1132–1139.PubMed
286.
Spratlin, J. L., Serkova, N. J., & Eckhardt, S. G. (2009). Clinical applications of metabolomics in oncology: A review. Clinical Cancer Research, 15(2), 431–440.PubMed
287.
Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 457(7231), 910–914.PubMed
Metadata
Title
Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer
Authors
Raj Chari
Kelsie L. Thu
Ian M. Wilson
William W. Lockwood
Kim M. Lonergan
Bradley P. Coe
Chad A. Malloff
Adi F. Gazdar
Stephen Lam
Cathie Garnis
Calum E. MacAulay
Carlos E. Alvarez
Wan L. Lam
Publication date
01-03-2010
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-010-9199-2

Other articles of this Issue 1/2010

Cancer and Metastasis Reviews 1/2010 Go to the issue

NON-THEMATIC REVIEW

Important role of integrins in the cancer biology

EditorialNotes

Preface

NON-THEMATIC REVIEW

Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives

NON-THEMATIC REVIEW

The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment

OriginalPaper

EGFR mutations and the terminal respiratory unit

NON-THEMATIC REVIEW

Modeling prostate cancer: a perspective on transgenic mouse models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits